LAS VEGAS, NV / ACCESSWIRE / July 25, 2016 / Biotechnology companies have been making significant progress towards fighting cancer. Peter Evans, of the UK Times, sees a number of companies expanding their portfolio with potential new drug combinations that may finally beat this killer disease.

Larger drug makers are scouring early development, preclinical and clinical stage biotechs looking for emerging treatments and drugs that could, in concert with their products, beat cancer.

This could have significant implications for innovative new approaches, like Propanc Health Group Corporation's lead product, PRP. The Company recently announced they have engaged the services of two advisory firms in North America, Maxim Group LLC and Partner International Inc., to explore potential strategic partnering opportunities for the company's PRP treatment.

Propanc Health Group Corporation (PPCH), is an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers.

The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer.

According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.

Propanc (PPCH) has just announced significant progress of development activities ahead of the First­In­Man studies for their PRP treatment.

First­In­Man studies are exactly what they sound like, the first studies on human subjects, in some circles it is referred to as Phase 0. Why is this big?

Because this means PPCH is close to becoming a clinical stage biotechnology company. This is a major milestone on the horizon. There are also several markers in between which should make for exciting announcements and could help bring this oversold company back to its 2015 highs.

Point is, Propanc appears to be sitting at a bottom, and potentially has a litany of positive announcements ahead. Now would be a great time to buy your tickets for what should be a fun ride heading into next year's trials.

Tobira Therapeutics (TBRA), a clinical stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from multiple animal models showed that cenicriviroc (CVC), apotent inhibitor of two chemokine receptors, displayed potent anti-inflammatory and anti­fibrotic activity in multiple organs including liver and kidney. The results from this study have been published in the journal PLOS ONE (http://dx.doi.org/10.1371/journal.pone.0158156).

Rock Creek Pharmaceuticals, Inc. (RCPI) has been on quite a run this week, and momentum is showing no signs of slowing.

Mast Therapeutics, Inc. (MSTX) San Diego, California headquartered clinical stage biopharmaceutical Company, Mast Therapeutics Inc.'s stock ended the day 1.40% higher at $0.46. A total volume of 2.99 million shares was traded, which was higher than their three months average volume of 2.36 million shares. The Company's shares have surged 47.19% in the last month, 82.52% over the previous three months, and 8.64% on an YTD basis. The stock is trading 31.20% above its 50­day moving average and 19.87% above its 200­day moving average. Additionally, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have an RSI of 74.39.

Vitae Pharmaceuticals, Inc. (VTAE), gapped higher in March in strong volume. It consolidated that move for 2 months in a wide range before racing higher, closing the gap down from March in the process. Since then it has been consolidating in a very tight range under the 200 day SMA. The RSI is in the bullish range and has reset from an overbought condition. The MACD has also reset lower. Look for a move over resistance to participate to the upside.

Cytokinetics, Inc. (CYTK) announced that the results from the ATHENA Trials have been published and are now available online in Catheterization and Cardiovascular Interventions, a leading international journal covering the broad field of cardiovascular diseases and the official journal of The Society for Cardiovascular Angiography and Interventions that has over 4,300 interventional and invasive cardiologist members in over 70 countries.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC